ABUSE RESISTANT TRANSDERMAL BUPRENORPHINE FOR OPIATE

阿片受体拮抗剂治疗是近期戒断的重要治疗手段 吸毒成瘾的人。丁丙诺啡是一种激动剂-拮抗剂混合的药物 防止吗啡类药物产生任何快感的特性，从而 消除生理强化。Biotek建议改进 通过开发一种经皮给药系统进行拮抗治疗 丁丙诺啡，一种非常有效的药物，受试者更喜欢 美沙酮或纳曲酮。丁丙诺啡透皮贴剂可避免 不方便频繁就诊，并稳定维护 丁丙诺啡的次级兴奋作用应提供更多的积极作用 加强和提高合规性。因为丁丙诺啡对 为了防止滥用，Biotek建议通过以下方式保护补丁免受颠覆 加入一种对皮肤无活性的纳洛酮，这是一种中和药物 丁丙诺啡的轻度欣快感和催促戒断 如果静脉注射鸦片类药物的话。Biotek之前已经证明了高 丁丙诺啡的透皮释放率。在第一阶段，我们将尝试 丁丙诺啡从一种配方中获得类似的速率 含有对皮肤无活性的纳洛酮，其目标是开发一种 耐滥用48小时丁丙诺啡贴片。

Opiate antagonist therapy is an important treatment for recently withdrawn narcotic addicts. Buprenorphine is a drug with mixed agonist-antagonist properties which prevents any high from morphine-like drugs, thereby eliminating physiological reinforcement. BIOTEK proposes to improve antagonist therapy by developing a transdermal delivery system for buprenorphine, a very effective drug preferred by subjects to either methadone or naltrexone. Transdermal buprenorphine would avoid the inconvenience of frequent clinical visits, and steady maintenance of the secondary agonist action of buprenorphine should provide more positive reinforcement and improve compliance. Because buprenorphine is susceptible to abuse, BIOTEK proposes to protect the patches against subversion by adding a transdermally inactive form of naloxone, a drug which counteracts the mild euphoria of buprenorphine and precipitates withdrawal from other opiates if taken intravenously. BIOTEK has previously demonstrated high transdermal delivery rates for buprenorphine. In Phase I we will attempt to achieve similar rates for buprenorphine from a formulation which contains transdermally inactive naloxone, with the goal of developing an abuse-resistant 48 hour buprenorphine patch.